Skip to main content
Advertisement
Advertisement

ACRV

ACRV logo

Acrivon Therapeutics, Inc. Common Stock

2.06
USD
Sponsored
-0.09
-4.19%
Sep 23, 15:59 UTC -4
Closed
exchange

After-Market

2.14

+0.08
+3.69%

ACRV Earnings Reports

Positive Surprise Ratio

ACRV beat 12 of 15 last estimates.

80%

Next Report

Date of Next Report
Nov 11, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$0.46
Implied change from Q2 26 (Revenue/ EPS)
--
/
+6.98%
Implied change from Q3 25 (Revenue/ EPS)
--
/
-2.13%

Acrivon Therapeutics, Inc. Common Stock earnings per share and revenue

On Aug 12, 2026, ACRV reported earnings of -0.43 USD per share (EPS) for Q2 26, beating the estimate of -0.51 USD, resulting in a 15.69% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +7.56% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 8 analysts forecast an EPS of -0.46 USD, with revenue projected to reach -- USD, implying an increase of 6.98% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Champions Oncology, Inc.
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.01
Actual
-$0.03
Surprise
-194.12%
logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Acrivon Therapeutics, Inc. Common Stock reported EPS of -$0.43, beating estimates by 15.69%, and revenue of $0.00, 0% as expectations.
The stock price moved up 7.56%, changed from $1.72 before the earnings release to $1.85 the day after.
The next earning report is scheduled for Nov 11, 2026.
Based on 8 analysts, Acrivon Therapeutics, Inc. Common Stock is expected to report EPS of -$0.46 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement